R3 Bio develops cell-based research platforms using cellular reprogramming, stem-cell-derived systems, and advanced analytical methods. We are pursuing multiple research programs to better model human biology in vitro and evaluate where next-generation New Approach Methodologies (NAMs) may improve preclinical research. Our near-term focus is on experimental cell-culture systems and model validation, with the long-term goal of reducing reliance on animal studies in selected applications where the data support that use.
Biology in Service of Life
What Sets R3 Bio Apart
Cell-Based Platforms for Next-Generation Preclinical Research. We combine cellular reprogramming, stem-cell-derived systems, and analytical tools to study human biology in vitro and evaluate more predictive, ethically preferable research models.
R3 Bio is advancing several complementary research programs—from cellular reprogramming and stem-cell-derived model systems to computational analysis to build more informative approaches for studying human biology in vitro. Our work is designed to evaluate whether more integrated model systems can support selected NAM applications over time and help reduce reliance on animal studies where scientifically appropriate.
NAMs-Driven Platforms
Experimental in vitro systems built from stem cells to study biologically relevant processes in controlled settings.
Integrated Biological Signaling
Research aimed at capturing bioelectrical and other cross-cellular signals that are often lost in simpler assays
Regulatory-Aligned Science
Research infrastructure developed in response to institutions like the NIH—supporting validation, transparency, and responsible adoption across industry.
Mutiple Paths
Better Models
In Vitro Model Development
Design and validation of human-based biological systems that replace animal studies where appropriate and improve the predictive power of preclinical research.
NAMs Implementation
Deployment of New Approach Methodologies aligned with regulatory modernization efforts—helping partners adopt next-generation testing strategies with confidence.
Computational Analysis
Computational platforms that accelerate data interpretation, surface biological signals earlier, and streamline complex experimental pipelines.
Regulatory-Ready Translation
Research programs structured for validation, reproducibility, and evolving agency expectations—supporting faster progression from laboratory insight to clinical decision.
Industry Engagement & Scientific Forums
Here are some frequently asked questions
90
%
of drug candidates still fail in human trials.
What is your research based on?
All current and unpublished research activities are cell culture–based and focused on in vitro systems. We believe that such models can reduce and replace suffering live animals in many research applications.
Where are we based?
San Francisco with an upcoming second location in Puerto Rico.
Is this work about ethics or scientific performance?
It is both. Humane research practices and scientific rigor are not in conflict. More accurate, models improve data quality while reducing unnecessary animal use, aligning ethical responsibility with better scientific outcomes.
Recent Media Coverage
We noted recent media coverage projecting certain peculiar intentions on our company.
R3 Bio is not in fact working on any large scale "organ sacks", "brainless animals" or whatever these articles insinuate. We do not condone such claims in any way. Our work involves molecules, cell cultures and microscopic structures.
To the extent that such work is being pursued by other groups, we hope they proceed carefully and responsibly, based on scientific evidence, ethical guardrails and transparency about the promise and the limits of the work.
Have you considered human applications?
R3 Bio is excited by the future prospect of human organ replacement, but views the science as not currently ready. With luck, technologies like ours may get there one day.